Shilpa Medicare Ltd is Rated Hold

Current Rating and Its Significance

MarketsMOJO’s 'Hold' rating for Shilpa Medicare Ltd indicates a balanced outlook for investors. It suggests that while the stock may not be an immediate buy, it is not recommended for sale either. This rating reflects a moderate risk-reward profile, where investors might consider maintaining their existing positions while monitoring the company’s performance closely. The rating was revised from 'Sell' to 'Hold' on 06 May 2026, accompanied by a notable improvement in the Mojo Score from 43 to 57, signalling enhanced confidence in the stock’s prospects.

Here’s How the Stock Looks Today

As of 03 August 2026, Shilpa Medicare Ltd exhibits a mixed but cautiously optimistic profile across key evaluation parameters: Quality, Valuation, Financial Trend, and Technicals. These factors collectively underpin the current 'Hold' rating and provide insight into the company’s investment appeal.

Quality Assessment

The company’s quality grade is assessed as below average, primarily due to its long-term fundamental strength. The average Return on Capital Employed (ROCE) stands at a modest 5.44%, reflecting limited efficiency in generating returns from its capital base over the years. Net sales have grown at an annualised rate of 11.30% over the past five years, while operating profit has expanded at 19.78%, indicating moderate but steady growth. Despite these figures, the company’s long-term growth trajectory remains subdued compared to sector peers, which tempers enthusiasm among quality-focused investors.

Valuation Considerations

Shilpa Medicare Ltd is currently classified as expensive based on valuation metrics. The stock trades at an Enterprise Value to Capital Employed (EV/CE) ratio of 3.9, which is relatively high. However, it is important to note that this valuation is at a discount compared to the average historical valuations of its peers, suggesting some relative value remains. The company’s Price/Earnings to Growth (PEG) ratio is 0.5, signalling that earnings growth is outpacing the price increase, which can be attractive for growth-oriented investors. Nonetheless, the expensive valuation grade advises caution, as the stock price may already reflect much of the anticipated growth.

Financial Trend and Performance

The financial trend for Shilpa Medicare Ltd is very positive, supported by robust recent results. The company has declared positive earnings for 11 consecutive quarters, demonstrating consistent profitability. As of 03 August 2026, the latest quarterly Profit After Tax (PAT) stood at ₹85.40 crores, growing by 81.2% compared to the previous four-quarter average. The half-year ROCE has improved to 10.52%, nearly doubling the long-term average, while quarterly PBDIT reached a record ₹119.71 crores. Net profit growth over the past year has surged by 99.09%, reflecting strong operational momentum. These figures highlight a significant turnaround in financial health and earnings quality, which supports the current rating.

Technical Outlook

From a technical perspective, the stock is rated bullish. Price action over recent months has been strong, with the stock delivering a 51.94% return over the past three months and an impressive 105.95% gain over six months. Year-to-date returns stand at 92.48%, and the one-year return is 44.24%, outperforming the BSE500 index consistently over the last three years. The stock’s upward momentum is further supported by a positive day change of 1.1% on 03 August 2026, indicating sustained investor interest and buying pressure. This bullish technical grade suggests that the stock’s price trend remains favourable in the near term.

Shareholding and Market Capitalisation

Shilpa Medicare Ltd is classified as a small-cap company within the Pharmaceuticals & Biotechnology sector. The majority of its shares are held by non-institutional investors, which may contribute to higher volatility but also indicates strong retail participation. This ownership structure can influence trading patterns and liquidity considerations for investors.

Investment Implications

For investors, the 'Hold' rating on Shilpa Medicare Ltd suggests a cautious stance. The company’s recent financial performance and technical strength provide reasons for optimism, particularly given the strong profit growth and positive price momentum. However, the below-average quality grade and expensive valuation indicate that risks remain, especially if growth slows or market sentiment shifts.

Investors currently holding the stock may consider maintaining their positions to benefit from ongoing earnings momentum and sector tailwinds. Prospective investors should weigh the company’s growth potential against its valuation premium and monitor quarterly results closely for signs of sustained improvement or emerging challenges.

Summary of Key Metrics as of 03 August 2026

• Mojo Score: 57.0 (Hold)
• Market Cap: Small Cap
• Return on Capital Employed (5-year average): 5.44%
• Net Sales Growth (5-year CAGR): 11.30%
• Operating Profit Growth (5-year CAGR): 19.78%
• Quarterly PAT: ₹85.40 crores (81.2% growth vs previous 4Q average)
• Half-Year ROCE: 10.52%
• Quarterly PBDIT: ₹119.71 crores (highest recorded)
• Enterprise Value to Capital Employed: 3.9
• PEG Ratio: 0.5
• Returns: 1D +1.10%, 1M +1.59%, 3M +51.94%, 6M +105.95%, YTD +92.48%, 1Y +44.24%

In conclusion, Shilpa Medicare Ltd’s current 'Hold' rating reflects a nuanced view that balances strong recent financial and technical performance against valuation concerns and moderate quality metrics. Investors should consider these factors carefully when making portfolio decisions and remain attentive to upcoming quarterly results and sector developments.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →